Literature DB >> 118925

Respiratory syncytial virus infection in owl monkeys: viral shedding, immunological response, and associated illness caused by wild-type virus and two temperature-sensitive mutants.

G A Prince, S C Suffin, D A Prevar, E Camargo, D L Sly, W T London, R M Chanock.   

Abstract

Intranasal inoculation of owl monkeys with wild-type respiratory syncytial virus induced upper respiratory tract disease in each of seven animals. The response of owl monkeys to two highly defective, temperature-sensitive, multiple-lesion mutants was then compared to the pattern seen with wild-type respiratory syncytial virus. These mutants, ts-1 NG-1 and ts-1 NG-16, were derived from the ts-1 mutant that had been remutagenized with nitrosoguanidine (NG). Previously the ts-1 NG-1 and ts-1 NG-16 mutants had been shown to be more temperature sensitive and more stable genetically than their ts-1 parent. Both ts-1 NG-1 and ts-1 NG-16 produced infection that was delayed in onsent compared to wild-type virus infection. However, the mutants were shed from the upper respiratory tract for the same period of time and at the same titer as wild-type virus. The serum neutralizing antibody response to infection with the mutants was nearly equivalent to that elicited by wild-type virus. However, the extent of disease induced by the mutants was significantly less than that seen with wild-type virus. These observations suggest that the mutants are potential vaccine condidates and should be subjected to additional in vivo testing in primates and, ultimately, humans.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 118925      PMCID: PMC414720          DOI: 10.1128/iai.26.3.1009-1013.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  Evaluation of five temperature-sensitive mutants of respiratory syncytial virus in primates: I. Viral shedding, immunologic response, and associated illness.

Authors:  L S Richardson; R B Belshe; W T London; D L Sly; D A Prevar; E Camargo; R M Chanock
Journal:  J Med Virol       Date:  1978       Impact factor: 2.327

2.  Experimental respiratory syncytial virus pneumonia in cebus monkeys.

Authors:  L S Richardson; R B Belshe; D L Sly; W T London; D A Prevar; E Camargo; R M Chanock
Journal:  J Med Virol       Date:  1978       Impact factor: 2.327

3.  Experimental respiratory syncytial virus infection of four species of primates.

Authors:  R B Belshe; L S Richardson; W T London; D L Sly; J H Lorfeld; E Camargo; D A Prevar; R M Chanock
Journal:  J Med Virol       Date:  1977       Impact factor: 2.327

4.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

5.  An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.

Authors:  A Z Kapikian; R H Mitchell; R M Chanock; R A Shvedoff; C E Stewart
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

6.  Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population.

Authors:  J Chin; R L Magoffin; L A Shearer; J H Schieble; E H Lennette
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

7.  Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants.

Authors:  P F Wright; T Shinozaki; W Fleet; S H Sell; J Thompson; D T Karzon
Journal:  J Pediatr       Date:  1976-06       Impact factor: 4.406

8.  The pathogenesis of respiratory syncytial virus infection in infant ferrets.

Authors:  G A Prince; D D Porter
Journal:  Am J Pathol       Date:  1976-02       Impact factor: 4.307

9.  The pathogenesis of respiratory syncytial virus infection in cotton rats.

Authors:  G A Prince; A B Jenson; R L Horswood; E Camargo; R M Chanock
Journal:  Am J Pathol       Date:  1978-12       Impact factor: 4.307

10.  Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.

Authors:  V A Fulginiti; J J Eller; O F Sieber; J W Joyner; M Minamitani; G Meiklejohn
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

View more
  12 in total

1.  Parenteral immunization with live respiratory syncytial virus is blocked in seropositive cotton rats.

Authors:  G A Prince; R L Horswood; E Camargo; S C Suffin; R M Chanock
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

2.  Infant baboons infected with respiratory syncytial virus develop clinical and pathological changes that parallel those of human infants.

Authors:  James F Papin; Roman F Wolf; Stanley D Kosanke; Justin D Jenkins; Sara N Moore; Michael P Anderson; Robert C Welliver
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-02-15       Impact factor: 5.464

Review 3.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

4.  Infection of marmosets with parainfluenza virus types 1 and 3.

Authors:  J D Hawthorne; D Lorenz; P Albrecht
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

5.  Viral respiratory diseases: vaccines and antivirals.

Authors:  E H Lennette
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

Review 6.  Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma.

Authors:  Shyam S Mohapatra; Sandhya Boyapalle
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

7.  Protection of rabbits against experimental pasteurellosis by a streptomycin-dependent Pasteurella multocida serotype 3:A live mutant vaccine.

Authors:  Y S Lu; S P Pakes
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

8.  Cell-mediated immune response to respiratory syncytial virus infection in owl monkeys.

Authors:  W C Koff; F R Caplan; S Case; S B Halstead
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

9.  Topically administered immunoglobulin reduces pulmonary respiratory syncytial virus shedding in owl monkeys.

Authors:  V G Hemming; G A Prince; W T London; P A Baron; R Brown; R M Chanock
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

Review 10.  Animal models of respiratory syncytial virus infection.

Authors:  Geraldine Taylor
Journal:  Vaccine       Date:  2016-11-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.